<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03946293</url>
  </required_header>
  <id_info>
    <org_study_id>Wholegrain_FMD</org_study_id>
    <nct_id>NCT03946293</nct_id>
  </id_info>
  <brief_title>Enhanced Vascular Function Following Intake of Feruloyl Esterase-processed High Fibre Bread.</brief_title>
  <official_title>Increased Bioavailability of Phenolic Acids and Enhanced Vascular Function Following Intake of Feruloyl Esterase-processed High Fibre Bread: a Randomized, Controlled, Single Blind, Crossover Human Intervention Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Reading</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biotechnology and Biological Sciences Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Reading</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the impact of a high phenolic acid intake from wholegrain wheat bread on
      human vascular function and plasma phenolic acid concentrations in healthy adults. All
      participants received a high fibre flatbread with enzymatically released free FA (14.22 mg),
      an equivalent standard high fibre bread (2.34 mg), or a white bread control (0.48 mg).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinical trial data have indicated an association between wholegrain consumption and a
      reduction in surrogate markers of cardiovascular disease. A number of components of wheat
      have been suggested to contribute to the cardiovascular health benefits associated with
      wholegrain consumption, most notably the fiber component. However, phenolic compounds that
      are bound to arabinoxylan fibre, particularly the hydroxycinnamate ferulic acid, may also
      contribute, in part, to vascular health effects. These phenolics may be more active when
      released enzymatically from the fiber prior to ingestion.

      The aim of the present study was therefore to determine whether the intake of high fibre
      bread containing higher free ferulic acid levels (enzymatically released during processing)
      enhances human endothelium-dependent vascular function to a greater extent than that of
      traditional wholegrain bread and/or a white bread control.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 5, 2015</start_date>
  <completion_date type="Actual">November 15, 2015</completion_date>
  <primary_completion_date type="Actual">June 30, 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Flow-mediated dilatation (FMD)</measure>
    <time_frame>Change from baseline to 5 hours</time_frame>
    <description>FMD of the brachial artery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma phenolic acids</measure>
    <time_frame>Change from baseline to 24 hours</time_frame>
    <description>Presence of phenolic acid metabolites in the circulation over a 24 h period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laser Doppler Imaging with iontophoresis</measure>
    <time_frame>Change from baseline to 5 hours</time_frame>
    <description>Laser Doppler Imaging with iontophoresis (acetyl choline and sodium nitroprusside)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Digital Volume Pulse (DVP)</measure>
    <time_frame>Change from baseline to 5 hours</time_frame>
    <description>DVP stiffness index (DVP-SI) and DVP reflexion index (DVP-RI)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Cardiovascular Risk Factor</condition>
  <arm_group>
    <arm_group_label>White bread</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>White bread 3 x 30 g, single serving</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Wholegrain</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard wholegrain, 3 x 30 g, single serving</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Wholegrain Enzyme</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enzyme-treated wholegrain, 3 x 30 g, single serving</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>White Bread</intervention_name>
    <description>White bread made with commercial white flour with bran/fibre removed</description>
    <arm_group_label>White bread</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Wholegrain bread</intervention_name>
    <description>Wholegrain bread made with commercial wholegrain flour.</description>
    <arm_group_label>Wholegrain</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Wholegrain Enzyme</intervention_name>
    <description>Wholegrain bread made with enzyme-treated commercial wholegrain flour.</description>
    <arm_group_label>Wholegrain Enzyme</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1) fasting lipids in the upper half of the normal range (triacylglycerol 0.8-3.2 mmol/l and
        total cholesterol 6.0-8.0 mmol/l); 2) BMI 25-32 kg/m2; 3) non-smoker; 4) not diabetic
        (diagnosed or fasting glucose &lt; 7 mmol/l) or suffer from endocrine disorders; 5) hemoglobin
        and liver enzymes levels within the normal range [Alanine Transaminase (ALT): 0-55 IU/L;
        Alkaline Phosphatase (ALP): 38-126 U/L; Aspartate Transaminase (AST): 0-45 IU/L; Gamma
        Glutamyl Transferase (GGT): 12-58 IU/L]); 6) not having suffered a myocardial
        infarction/stroke in the past 12 months; 7) not suffering from renal or bowel disease or
        have a history of choleostatic liver or pancreatitis; 8) not on drug treatment for
        hyperlipidemia, hypertension, inflammation or hyper-coagulation; 9) not taking any fish
        oil, fatty acid or vitamin and mineral supplements; 10) no history of alcohol misuse; 11)
        not planning, or on a weight reduction regime; 12) not having taken antibiotics in the 6
        months prior to the study; and 13) being able to consume the study interventions.

        Exclusion Criteria:

          -  Gluten sensitive
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Food and Nutritional Sciences</name>
      <address>
        <city>Reading</city>
        <state>Berkshire</state>
        <zip>RG6 6AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 8, 2019</study_first_submitted>
  <study_first_submitted_qc>May 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2019</study_first_posted>
  <last_update_submitted>May 9, 2019</last_update_submitted>
  <last_update_submitted_qc>May 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Reading</investigator_affiliation>
    <investigator_full_name>Jeremy Paul Edward Spencer</investigator_full_name>
    <investigator_title>Professor of Nutritional Medicine</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

